Immediately preoperative use of biological therapy does not influence liver regeneration after large resection - Porcine experimental model with monoclonal antibody against epidermal growth factor

In Vivo

Volumn 26, Issue 4, 2012, Pages 683-691

  Liska, V ^a   Treska, V ^a   Mirka, H ^a   Benes, J ^a   Vycital, O ^a   Bruha, J ^a   Pitule, P ^a   Skalicky, T ^a   Sutnar, A ^a   Chlumska, A ^a   Racek, J ^a   Trefil, L ^a   Finek, J ^a   Holubec, Lubos ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Biological therapy; Cetuximab; Epidermal growth factor; Epidermal growth factor receptor; Liver regeneration; Liver surgery; Porcine model

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; AMINOPENICILLIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CETUXIMAB; CHOLINESTERASE; CLAVULANIC ACID; CREATININE; EPIDERMAL GROWTH FACTOR; GAMMA GLUTAMYLTRANSFERASE; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA1; UREA;

ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOLOGICAL THERAPY; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER SURGERY; CELL PROLIFERATION; CELL SIZE; CHEMICAL ANALYSIS; CHOLINESTERASE BLOOD LEVEL; CONTROLLED STUDY; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; DISEASE MODEL; DRUG EFFECT; ECHOGRAPHY; EXPERIMENTAL MODEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOASSAY; LIVER BIOPSY; LIVER CANCER; LIVER CELL; LIVER FUNCTION; LIVER LOBECTOMY; LIVER PARENCHYMA; LIVER REGENERATION; LIVER RESECTION; LIVER WEIGHT; NONHUMAN; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; PROTEIN BLOOD LEVEL; STATISTICAL PARAMETERS; STATISTICAL SIGNIFICANCE; SUPERIOR CAVA VEIN; SWINE; UREA BLOOD LEVEL; WILCOXON SIGNED RANKS TEST;

EID: 84865081007     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Clavien PA, Petrowsky H, DeOliveira ML and Graf R: Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 356: 1545-1559, 2007.
2. Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B, Bralet MP, Bouchahda M, Machover D, Ducreux M, Castagne V, Azoulay D and Castaing D: Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25(29): 4593-4602, 2007.
3. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L and Fong Y: Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 7(1): 109-115, 2003.
4. Mentha G, Majno PE and Roth AD: Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 93(7): 872-878, 2006.
5. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W and Gruenberger T: EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD).Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617): 1007-1016, 2008.
6. Kopetz S and Vauthey JN: Perioperative chemotherapy for resectable hepatic metastases.Lancet 371(9617): 963-965, 2008.
7. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G and Terris B: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15(3): 460-466, 2004.
8. Folprecht G, Grothey A, Alberts S, Raab HR and Köhne CH: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16(8): 1311-1319, 2005.
9. Chaudhury P, Hassanain M, Bouganim N, Salman A, Kavan P and Metrakos P: Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. HPB (Oxford) 12(1): 37-42, 2010.
10. Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW, Allan JM, Parmar MK, Quirke P and Seymour MT: Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol 27(33): 5519-5528, 2009.
11. Bilchik AJ, Poston G, Curley SA, Strasberg S, Saltz L, Adam R, Nordlinger B, Rougier P and Rosen LS: Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 23(36): 9073-9078, 2005.
12. Poston GJ: The use of irinotecan and the treatment of advanced colorectal cancer. Eur J Surg Oncol 31: 325-330, 2005.
13. Rubbia-Brandt L, Mentha G and Terris B: Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. J Am Coll Surg 202(1): 199-200, 2006.
14. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH et al: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 13(12): 2936-2943, 1995.
15. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG and Strasberg SM: Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200(6): 845-853, 2005.
16. Bertolini F, Malavasi N, Scarabelli L, Fiocchi F, Bagni B, Del Giovane C, Colucci G, Gerunda GE, Depenni R, Zironi S, Fontana A, Pettorelli E, Luppi G and Conte PF: FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br J Cancer 104(7): 1079-84, 2011.
17. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari, G, Trigila N, Vellone M, Giuliante F, Nuzzo G and Barone C: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15(6): 933-939, 2004.
18. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F and Köhne CH: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11(1): 38-47, 2010.
19. Zorzi D, Chun YS, Madoff DC, Abdalla EK and Vauthey JN: Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 15(10): 2765-2772, 2008.
20. Kemeny N: Presurgical chemotherapy in patients being considered for liver resection.Oncologist 12(7): 825-839, 2007.
21. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P and Ciardiello F: Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. J Clin Oncol 29(15): 2011-2019, 2011.
22. Blonski W and Lichtenstein GR: Safety of biologic therapy. Inflamm Bowel Dis 13(6): 769-796, 2007.
23. Sorscher SM: Biological therapy update in colorectal cancer. Expert Opin Biol Ther 7(4): 509-519, 2007.
24. Fausto N and Riehle KJ: Mechanisms of liver regeneration and their clinical implications. J Hepatobiliary Pancreat Surg 12: 181-189, 2005.
25. Michalopoulos GK: Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol 176(1): 2-13, 2010.
26. Michalopoulos GK: Liver regeneration: Alternative epithelial pathways. Int J Biochem Cell Biol 43(2): 173-179, 2011.
27. Liska V, Slowik P, Eggenhofer E, Treska V, Renner P, Popp FC, Mirka H, Kobr J, Sykora R, Schlitt HJ, Holubec L, Chlumska A, Skalicky T, Matejovic M and Dahlke MH: Intraportal Injection of Porcine Multipotent Mesenchymal Stromal Cells Augments Liver Regeneration after Portal Vein Embolization. In Vivo 23: 229-235, 2009.
28. Delgado-Rizo V, Salazar A, Panduro A and Armendariz-Borunda J: Treatment with anti-transforming growth factor beta antibodies influences an altered pattern of cytokines gene expression in injured rat liver. Biochim Biophys Acta 1442(1): 20-27, 1998.
29. Mangnall D, Bird NC and Majeed AW: The molecular physiology of liver regeneration following partial hepatectomy. Liver international 23: 124-138, 2003.
30. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK.Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94(3): 274-286, 2007.
31. Wicherts DA: Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases, British Journal of Surgery 98: 399-407, 2011.
32. D'Angelica M, Kornprat P and Jarnagin WR: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 14(2): 759-765, 2007.
33. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK and Kopetz S: Preoperative bevacizumab does notsignificantly increase postoperative complication rates in patients undergoing hepatic Sumery for colorectal liver metastases. J Clin Oncol 26: 5254-5260, 2008.
34. Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ and Hill SE: Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regiment does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206: 96-106, 2008.
35. Ellis LM, Curley SA and Grothey A: Surgical resection after downsizing of colorectal liver metastasis in the era of bavacizumab. J Clin Oncol 23: 4853-4855, 2005.
36. Aussilhou B, Dokmak S, Faivre S, Paradis V, Vilgrain V and Belghiti J: Preoperative liver hypertrophy induced by portal flow occlusion efore major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 16: 1553-1559, 2009.
37. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P and Ferguson KM: Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7(4): 301-311, 2005.
38. Zhang Z, Schwartz S, Wagner L and Miller W: A greedy algorithm for aligning DNA sequences. J Comput Biol 7(1-2): 203-214, 2000.
39. Liska V, Treska V, Mirka H, Kobr J, Sykora R, Skalicky T, Sutnar A, Bruha J, Fiala O, Vycital O, Chlumska A, Holubec L and Matejovic M: Interleukin-6 Augments Activation of Liver Regeneration in Porcine Model of Partial Portal Vein Ligation, Anticancer Res 29: 2371-2377, 2009.